Abstract 5605
Background
Staff who comes in contact with cytotoxic agents in conjunctions with preparation, administration, nursing care and cleaning are at risk for exposure. These hazardous drugs can alter DNA or affect other intracellular processes that interfere with cancer cell growth. Using personal protection equipment (PPE) and closed systems reduce but doesn’t eliminate the risks of exposure. Current guidelines vary between countries and few organization test exposure risks systematically.
Methods
We performed tests on occupational exposure (from 10 different health care surfaces) from three types of chemotherapy (Cyclophosphamide, Gemcitabine and Fluorouracil) from three different hospitals in Sweden. The tests were analyzed at an accredited lab according to protocol. We also collected survey data from cancer nurses on safety awareness, adherence to safety protocol and education from the same hospitals. Data on cleaning routines were also collected.
Results
Preliminary results showed exposure above recommended risk level at all three hospitals and for all three drugs. The survey data showed that nurses only partly follow the recommended PPE but all responded that they had knowledge and competence to handle cytotoxic drugs, even if 37 % reported not to receiving any education from the employer. Cleaning routines differed between the hospitals and may explain some of the exposures.
Conclusions
Nurses in chemotherapy care are exposed to cytotoxic drugs. Efforts are needed to reduce these occupational risks and managers need to adopt a systematic approach to test exposure risks and to intervene. Guidelines need to be revised and include recent research results. Clinical nurses should always use PPE.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Regionalt cancercentrum Stockholm-Gotland.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract